Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
64.78
+1.47 (2.32%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Verona Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 66.83, with a low estimate of 36 and a high estimate of 93. The average target predicts an increase of 3.16% from the current stock price of 64.78.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
The average analyst rating for Verona Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $74 → $93 | Buy | Maintains | $74 → $93 | +43.56% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $75 | Strong Buy | Maintains | $60 → $75 | +15.78% | Feb 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $44 → $72 | Strong Buy | Maintains | $44 → $72 | +11.15% | Feb 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $42 → $60 | Strong Buy | Reiterates | $42 → $60 | -7.38% | Jan 21, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $68 | Strong Buy | Initiates | $68 | +4.97% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
319.81M
from 42.28M
Increased by 656.43%
Revenue Next Year
618.43M
from 319.81M
Increased by 93.37%
EPS This Year
0.29
from -2.16
EPS Next Year
1.68
from 0.29
Increased by 474.83%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 418.9M | 857.0M | 1.2B | ||
| Avg | 319.8M | 618.4M | 842.7M | ||
| Low | 259.7M | 460.7M | 649.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 890.7% | 168.0% | 99.7% | ||
| Avg | 656.4% | 93.4% | 36.3% | ||
| Low | 514.3% | 44.1% | 4.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.87 | 4.55 | 3.81 | ||
| Avg | 0.29 | 1.68 | 2.38 | ||
| Low | -0.04 | 0.15 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,458.5% | 127.3% | ||
| Avg | - | 474.8% | 42.1% | ||
| Low | - | -49.6% | -72.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.